RASSF6

Across TCGA pan-cancer cohorts, RASSF6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RASSF6 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RASSF6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RASSF6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where RASSF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.907	0.535	.001	54	view →
PDAC	DFS	Quartile	II,III,IV	0.715	0.303	.002	24	view →
CCRCC	DFS	Quartile	All	1.000	0.441	.008	20	view →
LUAD	DFS	Median	II,III,IV	0.677	0.177	.016	12	view →
UCEC	OS	Median	All	0.981	0.886	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RASSF6–HNSC (DFS)

Open the HNSC breakdown →